To allow the committee to be a real link between Sanofi and the individual shareholders it represents, the Investor Relations team regularly informs it about the Company’s business and invites its members to participate in different communication activities. As a result, the committee members learn more about how a leading pharmaceutical company operates and are able to assess the challenges of an efficient shareholder communication.
Meeting with Serge Weinberg, Chairman of the Board
The Investor Relations team welcomed the Shareholder committee at Sanofi's headquarters in Paris to present full-year 2018 results. This first meeting of the year was also an opportunity to discuss communication projects in 2019 and prepare for the annual general meeting.
Serge Weinberg, Chairman of the Board, joined the group at lunch to discuss Sanofi's achievements in 2018 and answer questions on hot topics, perspectives and dividend policy.
Visit to the Sanofi Pasteur site of Marcy l'Etoile
On June 26, 2018, the Shareholders Committee visited the Sanofi Pasteur site of Marcy l'Étoile in the Lyon region, a center of scientific and industrial expertise for the production of vaccines to be exported worldwide. Welcomed by Deputy Site Director Alain Louvel and members of the site Executive Committee, the Shareholders Committee and the Investor Relations team visited the biologics' production and quality buildings.
Launch of the new signature “Empowering Life”
On December 19, 2017, the Individual Shareholder Committee gathered at Sanofi's headquarters in Paris to learn more about the first nine months of 2017 and discuss news around product launches, study results and share price evolution.
The committee also discovered the new signature of Sanofi: “Empowering Life”, expressing Sanofi’s mission to support people as a health journey partner.
Visit to Ambarès production site
On June 28, 2017, the Individual Shareholders Committee visited Sanofi’s Ambarès production site, near Bordeaux, France. Ambarès is a major manufacturing and packaging facility specialized in two types of production: dry formulas (tablets, coated tablets, capsules) and injectables in the form of ampoules. The site manufactures some of Sanofi’s key products in the areas of cardiovascular disease, central nervous system, epilepsy as well as consumer healthcare.
Visit of the Neuville-sur-Saône site
On June 22, 2016, the Individual Shareholders Committee visited the Neuville-sur-Saône site, near Lyon, France, the world’s first and only production facility of the dengue vaccine, Dengvaxia®.
The Neuville site is the third European production center of Sanofi Pasteur. It benefits from the proximity of the Marcy l’Etoile site, the largest vaccines research, development and production center worldwide and the global headquarters of Sanofi Pasteur in Lyon.
Visit of the Frankfurt production site
On June 5, 2015, the Individual Shareholders Committee went to one of Sanofi’s largest sites: Industriepark Höchst, in Frankfurt, Germany.
The committee was welcomed by members of the Sanofi Germany and Diabetes management team, as the German affiliate and the Global Diabetes division are headquartered on this site. Frankfurt-Höchst is the largest integrated Sanofi site where the complete diabetes product portfolio is manufactured using aseptic state-of-the-art manufacturing technologies.